848836-58-8

Basic information

• Product Name: Methanesulfonic acid, trifluoro-, 2,2,2-trifluoro-1-(4-fluorophenyl)ethyl ester
• CAS NO: 848836-58-8
• Molecular Formula: C9H5F7O3S
• Molecular Weight: 326.192
• Mol File: 848836-58-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Methanesulfonic acid, trifluoro-, 2,2,2-trifluoro-1-(4-fluorophenyl)ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Methanesulfonic acid, trifluoro-, 2,2,2-trifluoro-1-(4-fluorophenyl)ethyl ester(848836-58-8)
• EPA Substance Registry System: Methanesulfonic acid, trifluoro-, 2,2,2-trifluoro-1-(4-fluorophenyl)ethyl ester(848836-58-8)

Safety Data

• Hazardous Substances Data: 848836-58-8(Hazardous Substances Data)

Upstream product

• 655-32-3 2,2,2-trifluoro-1-(4-fluorophenyl)ethanone 
• 421-83-0 trifluoromethane sulfonyl chloride 
• 17556-41-1 2,2,2-trifluoro-1-(4-fluorophenyl)ethanol 

Downstream Products

• 880762-37-8 2(R)-[2,2,2-trifluoro-1(S)-(4-fluorophenyl)ethylamino]-3-tritylsulfanyl-propionic acid 
• 880762-38-9 2(R)-[2,2,2-trifluoro-1(R)-(4-fluorophenyl)ethylamino]-3-tritylsulfanyl-propionic acid 
• 849094-00-4 3-(2-difluoromethoxyphenylmethanesulfanyl)-2(R)-[2,2,2-trifluoro-1(RS)-(4-fluorophenyl)ethylamino]-propionic acid 

Relevant articles and documents

CATHEPSIN INHIBITORS FOR THE TREATMENT OF BONE CANCER AND BONE CANCER PAIN

The present invention is directed to methods of using compounds that are inhibitors of cysteine proteases, in particular, of both cathepsins S and K and optionally further cathepsins B and/or L in treating bone cancer. The present invention is directed to pharmaceutical compositions comprising these compounds for treating bone cancer and bone cancer pain, especially the pain associated with metastasis. A single compound can be used to ameliorate the pain, the injury to bone, while also reducing tumor growth, the risk of metastasis and/or invasiveness of the cancer.

SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them. The present invention is also directed to the use of these inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy.